BioCity based Sygnature Discovery, a world-leading integrated drug discovery and non-clinical solutions provider, has begun expanding into new state of the art laboratories at Bruntwood SciTech’s Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the...
BioCity Glasgow based ILC Therapeutics has announced that its unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 (the virus which causes COVID-19) in cell culture than other commercially-available Interferons such as Interferon alpha 2 and...
Leading early-stage drug discovery, purification specialist and contract research organisation (CRO) Reach Separations has expanded its Nottingham premises in the wake of increased demand for its chiral purification services. Reach Separations specialises in chromatography for the analysis and purification of small molecules, and has added 1580...
XenoGesis has been working with biopharmaceutical company Sitryx to support the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory disease in the fast-emerging area of immunometabolism. Sitryx turned to XenoGesis for its scientific expertise and influence in solving the complex...
One of Nottingham’s most successful bioscience companies is working towards developing a drug to help treat the deadly coronavirus. Sygnature Discovery, which moved into BioCity in Nottingham city centre in 2004, provides drug discovery and pre-clinical services and expertise to clients across the world. The company has more than...
BioAscent Discovery Limited has announced a three-fold increase in revenues during 2018, with projections on-track for a further 2.5-fold increase in 2019. These significant results have been driven by substantial contract wins for both BioAscent’s established compound management services and its newer integrated drug discovery offering....
BioAscent Discovery Limited’s COO, Dr Sylviane Boucharens, has been included in the BioBeat 2018 list of 50 Movers and Shakers in BioBusiness. Her nomination follows an incredibly successful year in which she has spearheaded the company’s expansion to become a fully integrated drug discovery CRO. Co-founded...
BioCity, Alderley Park based Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce that Cancer Research UK Manchester Institute (CRUK MI), has licensed Flare for fresh insights into structure-based drug design. “Putting easy-to use and visually...